Companies / OSX

OSTEOPORE LIMITED

ASX:OSXHealth Care Equipment & Services
693.6M shares on issueASX (delayed) · as of 28 July 2026$0.005price · delayed$3.1Mmarket cap · indicative
D
Dilution grade

Runway under 2 quarters; share count grew 503% in 24 months; 4 cash raises in 24 months

Cash runway0.7 quarters of funding
Share-count growth (24m)503.4%
Raise cadence (24m)4 cash raises
Options & rights overhang1.7% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

OSTEOPORE LIMITED's ordinary share count grew 503.4% between July 2024 and July 2026, to 694M shares. The company raised capital four times in that period for total disclosed proceeds of A$18.0M, most recently A$5.8M in April 2025. Options and rights on issue could convert into 12M new shares, equal to 1.7% of the current share count, with 0% of current shares in the money. At the March 2026 quarter the company reported A$600K in available cash, about 0.7 quarters of funding at its recent spending rate. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
1.7%
Max option dilution
0.0%
ITM option dilution
0
Raises · last 12 months
0.7 qtrs
Cash cover · under 2 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 693.6M per ASX (delayed) (28 July 2026).
237.9M405.2M572.5MDec 24Sept 25July 26Cash raise · 7 Apr 2025Cash raise · 27 Mar 2025Cash raise · 13 Feb 2025Cash raise · 23 Dec 2024

Cash runway

0.7 qtrs
Less than two quarters of funding at the recent spend rate — near-term funding pressure.
$600k available cash at quarter ended 31 Mar 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 31 Mar 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
23 July 20262A · quoted issueOSX : ORDINARY FULLY PAID693.6MAppendix 2A
22 June 20263G · unquotedOSX : ORDINARY FULLY PAID678.4MAppendix 3G
15 June 20263H · cancellationOSX : ORDINARY FULLY PAID678.4MAppendix 3H
8 June 20262A · quoted issueOSX : ORDINARY FULLY PAID678.4MAppendix 2A
12 May 20262A · quoted issueOSX : ORDINARY FULLY PAID626.4MAppendix 2A
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

4 cash raises in the last 24 months · 0 in the last 12 months

$5.8M
Capital raise
7 Apr 2025
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

1.7%
Total overhang · of current shares
0.0%
In the money · at current price
11.8M
Potential new shares
—
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
7 May 2025Michael KeenanOther———3Y notice
7 May 2025Daniel OwOther———3Y notice
7 May 2025Mark LeongOther138k25k—3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

23 July 2026Application for quotation of securities - OSX
13 July 2026First OSX custom orthopaedic implant delivered to Hainan
6 July 2026OSX & Zimmer gain craniofacial market access to Saudi Arabia
1 July 2026OSX completes co-development project for neurosurgical guide
29 June 2026First patient treated in OSX-PAH jaw reconstruction trial
28 June 2026First 2 patients treated in QCH cleft lip clinical trial
25 June 2026QCH cleft lip clinical study patient recruitment completed
23 June 2026OSX neuro products approved in a major centre in Thailand
22 June 2026Cleansing Notice
22 June 2026Notification regarding unquoted securities - OSX
22 June 2026$PFurther Drawdown of T2 of the Redeemable Convertible Notes
21 June 2026First OSX custom orthopaedic implant completed in Hong Kong
16 June 2026OSX & DKSH Malaysia dental launch First products delivered
15 June 2026Notification of cessation of securities - OSX
10 June 2026Becoming a substantial holder
9 June 2026Ceasing to be a substantial holder
8 June 2026Application for quotation of securities - OSX
1 June 2026OSX & QCH launch trial for nasoalveolar augment in children
28 May 2026Change in substantial holding
25 May 2026$POSX secures Hainan FDA approval for orthopaedic devices

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.